C07K 14/65
Insulin-like growth factors, i.e. somatomedins
Official title: Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
C07K14/65 (Insulin-like growth factors, i.e. somatomedins) appears on 449 US grants and 537 published applications in this corpus.
Search patents in C07K- Granted patents
- 449
- Published applications
- 537
- Assignees
- 253
- Inventors
- 987
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 1 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 6 | 0 |
| 1989 | 3 | 0 |
| 1990 | 1 | 0 |
| 1991 | 5 | 0 |
| 1992 | 12 | 0 |
| 1993 | 8 | 0 |
| 1994 | 9 | 0 |
| 1995 | 17 | 0 |
| 1996 | 7 | 0 |
| 1997 | 23 | 0 |
| 1998 | 23 | 0 |
| 1999 | 5 | 0 |
| 2000 | 13 | 0 |
| 2001 | 12 | 0 |
| 2002 | 8 | 11 |
| 2003 | 7 | 28 |
| 2004 | 9 | 17 |
| 2005 | 5 | 22 |
| 2006 | 15 | 26 |
| 2007 | 12 | 15 |
| 2008 | 12 | 24 |
| 2009 | 11 | 25 |
| 2010 | 16 | 18 |
| 2011 | 9 | 22 |
| 2012 | 10 | 22 |
| 2013 | 15 | 18 |
| 2014 | 14 | 26 |
| 2015 | 9 | 19 |
| 2016 | 12 | 25 |
| 2017 | 28 | 22 |
| 2018 | 12 | 20 |
| 2019 | 13 | 23 |
| 2020 | 16 | 25 |
| 2021 | 14 | 24 |
| 2022 | 16 | 21 |
| 2023 | 7 | 22 |
| 2024 | 11 | 23 |
| 2025 | 11 | 23 |
| 2026 | 10 | 16 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions for targeting muscle cells and uses thereof1 Sep 2026US 12,721,902 B2Cavalry Biosciences, Inc.
- Bi-specific fusion proteins25 Aug 2026US 12,715,937 B2Silver Creek Pharmaceuticals, Inc.
- Bi-specific fusion proteins4 Aug 2026US 12,698,347 B2Silver Creek Pharmaceuticals, Inc.
- Multi-targeted, tunable, sustained delivery of payloads to charged avascular tissues16 Jun 2026US 12,653,899 B2Massachusetts Institute of Technology
- Virus AAV/IGF2, genetic treatment method and use thereof in protein misfolding-related diseases, such as Huntington's disease2 Jun 2026US 12,642,872 B2Universidad De Chile
- Compositions for targeting muscle cells and uses thereof10 Sep 2026US 2026/0263620 A1Cavalry Biosciences, Inc.
- Stapled peptides10 Sep 2026US 2026/0265334 A1The Florey Institute of Neuroscience and Mental Health
- Expression of modified proteins in a peroxisome13 Aug 2026US 2026/0234647 A1The Regents of the University of California
- Methods of treatment using igf-1 chimeric proteins6 Aug 2026US 2026/0226132 A1Silver Creek Pharmaceuticals, Inc.
- Gene Therapy Constructs for the Treatment of Pompe Disease30 Jul 2026US 2026/0216373 A1Amicus Therapeutics, Inc.
Most cited
By later US patents
- Expression using fused genes providing for protein product297US 4,751,180 AChiron Corporation · 1988
- Process for bacterial production of polypeptides265US 5,789,199 AGenentech, Inc. · 1998
- Albumin fusion proteins comprising GLP-1 polypeptides198US 7,141,547 B2Human Genome Sciences, Inc. · 2006
- Albumin fusion proteins157US 6,905,688 B2Human Genome Sciences, Inc. · 2005
- Derivative of the tryptophan operon for expression of fused gene products145US 4,738,921 AEli Lilly and Company · 1988